Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Pediatricians in Private Practice (US)

Analysis of: France Backs Sanofi's HPV Vaccine Gardasil Over Glaxo's (online.wsj.com)
Sanofi's Gardisil, the first-to-market HPV vaccine for adolescent females, has been fairly widely accepted in the US, albeit with some concerns regarding adverse reactions and cost.  It is likely that EU sales will gradually increase as the vaccine is accepted in Europe as well.
Analysis of: DC passes pharma rep licensing bill (www.fiercepharma.com)
OK, so now to peddle pharmaceuticals to doctors in D.C., a drug company will have to license their reps.  This will be a pain in the neck to the reps and those who supervise them, and will probably result in a small increase in the cost of doing business for detail people -- but I don't see how...
Analysis of: QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome (www.prnewswire.com)
Before addressing all the practical obstacles that might face Ophena, it might be helpful to acknowledge all the problems already faced by established drugs that are similar to it. The most similar would be Evista, another selective estrogen receptor modulator used primarily for osteoporosis, which...
Analysis of: Desmopressin Acetate (marketed as DDAVP Nasal Spray, DDAVP Rhinal Tube, DDAVP, DDVP, Minirin, and Stimate Nasal Spray) (www.fda.gov)
Intranasal desmopressin is rarely used now for nocturnal enuresis.  Most pediatricians have already converted to oral formulations.
Analysis of: Meridian Bioscience Receives FDA Clearance For Two New Rapid Tests For The Detection Of Influenza And Respiratory Syncytial Virus (www.medicalnewstoday.com)
Meridian's new RSV and Influenza A/B testing should provide new weapons for pediatricians during the upcoming flu and upper respiratory infection season.
Analysis of: New data for Menveo(TM) vaccine show excellent immune response and broad protection for infants against meningococcal meningitis (www.pipelinereview.com)
Novartis should be applauded for completing the earliest stages of a conjugated meningococcal vaccine for infants and young toddlers.  However, it is conceivable that Novartis' Menveo may be cannibalized in the market by sanofi's Menactra. Menactra is an already FDA-approved conjugated meningococcal...
Analysis of: FDA Issues Early Communication about an Ongoing Safety Review Of Aprotinin Injection (www.medicalnewstoday.com)
Aprotinin, a complex bovine protein with effects on clot dissolution, coagulation and enzymatic digestion, is without a doubt an innovative product. But innovation alone should not be the standard when the purpose of a drug is to improve patient outcomes. And so, whereas aprotinin is undoubtedly...
Analysis of: UCB Announces Initiation of Phase III Clinical Programme for RikeltaTM (brivaracetam) as Adjunctive Treatment in Partial-Onset Epilepsy (www.pipelinereview.com)
Epilepsy patients who have already failed to achieve control on two or three different regimens (be they single or multiple drug regimens) are unlikely to find success with any new regimen -- that's just the nature of the disease, unfortunately.  Failure on seizure medications is more a prognostic...
Analysis of: U.S. veterans dept to limit Glaxo's Avandia: report (www.reuters.com)
The United States Veterans Administration is probably the best HMO in the country, provided you are measuring the attainment of good clinical outcomes at reasonable cost.  Believe it or not, the VA, which has the unenviable task of providing healthcare to a relatively sick and historically disenfranchised...
Analysis of: New Allergic Rhinitis Treatment Avamys™ Receives Positive Opinion In Europe (www.medicalnewstoday.com)
From the standpoint of what is clinically practical, Avamys is not a new drug: it is fluticasone in a nasal spray, available for years as Flonase, now off patent and available in the U.S. generically and as Veramyst (the same product as Avamys). Despite claims that Avamys/Veramyst is the first drug...

Previous Page : 1 2 3 4 5 6 7 Next21 to 30 of 64

Analytics


Generated at 2009-01-07T19:00:58.307